1 September 2017 - - A new analysis showed lowering low-density lipoprotein cholesterol (LDL-C) levels with Repatha (evolocumab) reduced the risk of cardiovascular events in a sub-group of patients with a history of stroke from the Repatha cardiovascular outcomes study (FOURIER), US-based biotechnology company Amgen (NASDAQ: AMGN) said

No new safety concerns were identified in this cohort of more than 5,000 patients. Detailed results were presented TODAY in a Late-Breaking Clinical Trials session at the European Society of Cardiology Congress 2017 in Barcelona, Spain.

Nineteen percent of patients in the Repatha cardiovascular outcomes study had a prior history of non-hemorrhagic stroke (n=5,337). In this analysis, stroke patients treated with Repatha experienced a 56 % mean reduction in LDL-C levels, compared to placebo (median LDL-C level of 29 mg/dL for patients on Repatha versus median LDL-C of 89 mg/dL for placebo; p